ALXO earnings date and last-quarter result: next report 2026-08-11, last quarter miss, P/E -1.22. Updated 2026-07-23.
ALX Oncology Holdings (ALXO) Research Hub
ALX Oncology Holdings (ALXO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.13 USD (-3.42%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.22, market cap 0.27B. This hub links to the full technical, earnings and options research available for ALXO.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.13 USD (-3.42%) |
| 52-week range | 0.862 USD – 2.41 USD |
| Trend regime | Range |
| 14-day RSI | 51 (Neutral) |
| Trailing P/E | -1.22 |
| Market cap | 0.27B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for ALXO
Covered Call on ALXO: how it works, illustrative setup around the real 1.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ALXO: how it works, illustrative setup around the real 1.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ALXO: how it works, illustrative setup around the real 1.13 USD price, max profit/loss, breakeven and when to use it. Educational.
ALXO technical analysis: range, last 1.13 USD, RSI 51, 52w range 0.862 USD–2.41 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ALXO in?
ALX Oncology Holdings (ALXO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ALXO in an uptrend or downtrend?
As of 2026-10-26, ALXO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ALXO's trailing P/E ratio?
ALXO's trailing P/E is -1.22, with a market cap of 0.27B. See the earnings research page for full valuation detail.
When does ALXO next report earnings?
ALXO is next scheduled to report earnings on 2026-08-11.